


The European landscape of Research Infrastructures for the promotion of health: integration without overlapping

(G. Migliaccio, ISS, EATRIS-ERIC)

European Network of Excellence for Paediatric Clinical Research

DEVELOPMENT PIPELINE for novel drug





Academic driven translational medicine

- Intensive development by academia of newin-class drugs
- Progressive shifting from discovery to clinical proof of concepts
- Especially active in marginal markets
 - Rare diseases
 - Paediatric diseases of genetic origin



ESFRI Road Map

- Research Infrastructures of Pan-European design and interest are included in the Road Map document by the ESFRI committee.
- Development and Design are financed by dedicated EU funds (INFRA calls)
- They are maintained and controlled by the interested Member States.



Why European Research infrastructures?

The term 'research infrastructures' refers to **facilities**, **resources** and **related services** used by the scientific community to conduct top-level research in their respective fields

- Research infrastructures should:
 - have a pan-European interest
 - correspond to the long term needs of the European research communities
 - cover all scientific areas

An European Research Infrastructure seems to be an ideal research instrument for facilitating the joint establishment and operation in case of **complex and multidisciplinary** research activities.



BIO-MEDICAL SCIENCE RESEARCH INFRASTRUCTURES



biobanks



data



marine organisms



systems biology



translational research



mouse disease models



small molecules



microorganisms



· clinical trials



structural biology



biomedical imaging



BIO-MEDICAL SCIENCE RESEARCH INFRASTRUCTURES: ACCESSIBLE VIA CORBEL INNOVATION





• data



marine organisms



systems biology



mouse disease models



small molecules



microorganisms



structural biology



biomedical imaging



eatris

European infrastructure for translational medicine

OUR PURPOSE

EATRIS is a permanent EU biomedical research infrastructure.

Our purpose is to accelerate translation of science into medical products that benefit patients and improve human health.

OUR AIMS

- 1. Improving access to academic expertise
- 2. Increasing utilisation of academic infrastructure
- 3. Developing and validating tools that improve drug pipeline output
- 4. Facilitating public-private partnership in drug research



OUR SCOPE

- Preclinical discovery to clinical proof of concept
- Product platforms: Advanced Therapy Medicinal Products, Small Molecules, Vaccines
- Enabling platforms: Biomarkers, Imaging & Tracing

Disease and patient sex or age agnostic



ECRIN

 ECRIN is a public, non-profit organisation that links scientific partners and networks across Europe

to facilitate multinational clinical research. It provide sponsors and investigators with advice,

management services and tools to overcome hurdles to multinational trials and enhance collaboration.



PEDCRIN

 PedCRIN is a four-year INFRADEV3 project funded by the European Union's Horizon 2020 programme, launched on the 1st January 2017 (grant agreement number 731046) coordinated by ECRIN.

http://www.ecrin.org/projects/pedcrin



BBMRI ERIC

- Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium.
- BBMRI-ERIC shall establish, operate and develop a pan-European distributed research infrastructure of biobanks and biomolecular resources in order to facilitate the access to resources as well as facilities and to support high quality biomolecular and medical research.



EPTRI — European Paediatric Translational Research Infrastructure

TOPIC: Design Studies

Topic identifier: INFRADEV-01-2017
Publication date: 14 October 2015

Types of action: RIA Research and Innovation action

DeadlineModel: single-stage

Opening date: 08 December 2016

A feasibility study for the creation of an infrastructure dedicated to paediatric diseases




What is the scope for an Infrastructure dedicated solely to paediatric diseases?

- Regulatory request for safety studies in paediatric patients PIP
- Support for drug development directed to treat pediatric diseases
- Better understanding of the human development biology and pathophysiology
 - In utero
 - Neonatal
 - Juvenile



Conceptual Design Report (CDR): three phases

- 1- Context Analysis phase: to estimate the possible gaps to be covered
- 2 -Operational phase: to organize the different components of the new RI
- 3- Feasibility phase: to develop virtual exercises simulating the operations of the new RI.




WP2 EPTRI GOVERNANCE AND SUSTANAIBILITY DESIGN Leader: EATRIS, NL





EPTRI in the RIs landscape: no duplication but cooperation



European Network of Excellence for Paediatric Clinical Research



